{"filings":[{"id":471559,"accession_number":"0001213900-26-057828","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-05-15T20:29:39+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q1 revenue down 18% to $2.0M; net loss widens to $3.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $2.0M vs $2.4M YoY; U.S. sales fell 33% on generic L-Glutamine competition.","Net loss of $3.3M ($0.05 EPS) vs $2.3M ($0.04 EPS) YoY, driven by higher other expense.","Loss from operations improved 16% to $0.8M from $1.0M, reflecting cost-cutting measures.","MENA segment sales surged 446%, partially offsetting U.S. decline.","Cash and equivalents $1.1M at March 31, 2026, down from $2.1M at December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":1982000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99067,"accession_number":"0001213900-26-045250","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus appoints Henry H. Du to board; replaces resigned director Jon Kuwahara","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Henry H. Du appointed to fill board vacancy created by resignation of Jon Kuwahara; expected to become sole Audit Committee member.","Du is VP Finance & Accounting and interim CFO at Alpha Cognition (NASDAQ: ACOG); CPA with BA from Claremont McKenna.","No family relationships with other officers/directors; Du to be compensated on same basis as other directors.","Jon Kuwahara resigned from board; no reason provided in filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99066,"accession_number":"0001213900-26-043577","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Jon Kuwahara resigns from Emmaus Life Sciences board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Director Jon Kuwahara resigned from the board of Emmaus Life Sciences on April 13, 2026, effective April 15, 2026.","Willis Lee remains Chairman and Chief Executive Officer of Emmaus Life Sciences.","Emmaus Life Sciences has no securities registered under Section 12(b) of the Exchange Act and no trading symbol."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114870,"accession_number":"0001213900-26-036886","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus 2025 net revenue $12.5M (-25% YoY); net loss widens to $7.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $12.5M vs $16.7M in 2024; net loss $7.2M ($0.11/sh) vs $6.5M ($0.10/sh).","Income from operations $0.2M, improved from operating loss of $1.9M; operating expenses fell 34% to $11.4M.","Cash and equivalents $2.1M at Dec 31, 2025, up from $1.4M at Dec 31, 2024.","Entered license/distribution deal with NeoImmuneTech for U.S. operations, expected Q2 2026.","Revenue drop driven by generic L-Glutamine competition in U.S., partially offset by MENA growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114869,"accession_number":"0001213900-26-023644","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Emmaus enters Exclusive Supply Agreement with NeoImmuneTech for Endari in US/Canada","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement dated March 2, 2026; Emmaus to supply Endari (L-glutamine) exclusively to NIT for sickle cell disease in US and Canada.","Supply price is Emmaus' production cost plus a specified double-digit percentage margin.","Effective Date contingent on NIT obtaining necessary regulatory approvals and licensing; must occur by October 1, 2026.","Either party may terminate if Effective Date does not occur by Oct 1, 2026 (unless due to Emmaus' wrongful acts).","Exclusive Supply Agreement is a follow-up to the License Agreement reported on December 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131264,"accession_number":"0001213900-25-126728","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-31T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences licenses Endari to NeoImmuneTech for US/Canada with upfront and royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Emmaus grants NeoImmuneTech (NIT) exclusive rights to market Endari for sickle cell disease in US and Canada; upfront payment plus royalty on NIT sales.","Effective date conditioned on NIT obtaining regulatory approvals; either party may terminate if not met by Oct 1, 2026.","Emmaus will supply Endari to NIT at cost-plus margin; selected US sales force to transfer to NIT pending effective date.","If NIT fails to meet annual minimum sales, the license becomes non-exclusive.","Emmaus CEO says deal allows refocus on higher-growth regions: Middle East, Brazil, Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131263,"accession_number":"0001213900-25-124513","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences exchanges $3M note for $600K note and 6.33M shares (9% dilution)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $3M convertible note (10% interest, conversion $0.13) for $600K new note (10%, conversion $0.01 adjustable) and 6,332,692 shares valued at ~$0.38 each.","The 6.33M common shares represent 9.0% of total outstanding shares post-issuance.","New note is due on demand; conversion price adjusts quarterly based on average VWAP.","Issued under Section 3(a)(9) exemption with no additional consideration.","Holder Dong Seon Kim releases all claims under the old note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131262,"accession_number":"0001213900-25-123836","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Ian Zwicker resigns from Emmaus Life Sciences board, effective Dec. 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Zwicker resigned as director of Emmaus Life Sciences, effective December 31, 2025.","Resignation announced on December 15, 2025; filed on December 19, 2025.","No reason for resignation was disclosed; no successor has been named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131261,"accession_number":"0001213900-25-110878","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q3 net loss $2.1M; revenue down 38% YoY to $3.4M on generic competition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M ($0.03/share) vs net income of $1.8M in Q3 2024.","Revenue fell 38% to $3.4M from $5.5M; decline driven by generic L-Glutamine in U.S. and lower MENA sales.","Operating expenses reduced 43% to $2.4M due to workforce reduction and cost cuts.","Income from operations $0.7M vs $0.8M prior year, partially offsetting revenue drop.","Cash and equivalents dropped to $0.3M at Sept 30 from $1.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":8601000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147839,"accession_number":"0001213900-25-076672","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q2 net revenue down 48% to $2.8M; net loss narrows to $1.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $2.8M, down 48% YoY from $5.4M; competition from generic L-Glutamine cited.","Loss from operations $0.4M vs income of $0.6M in prior year.","Net loss $1.1M ($0.02/share) vs $2.2M ($0.03/share) in Q2 2024; decrease due to lower other expense.","Cash balance $0.9M at June 30, 2025, down from $1.4M at year-end 2024.","Operating expenses reduced 33% to $3.0M, primarily from headcount reduction in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":5223000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147838,"accession_number":"0001213900-25-060349","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus CFO Yasushi Nagasaki resigns effective June 30, 2025; Hiroko Huynh promoted to CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yasushi Nagasaki resigned as CFO, effective June 30, 2025, transitioning to full retirement.","Hiroko Huynh promoted to Chief Accounting Officer effective July 1, 2025.","Ms. Huynh, previously Controller since Jan 2020, joined Emmaus in Oct 2018 from Deloitte & Touche LLP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166557,"accession_number":"0001213900-25-044286","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q1 2025 net loss narrows to $2.3M; revenue flat at $2.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.3M ($0.04/sh) improved from $4.3M loss YoY; operating loss narrowed to $1.0M.","Net revenue $2.4M, down slightly from $2.5M YoY due to generic L-Glutamine competition.","Total operating expenses fell to $3.2M from $5.0M, mainly from workforce reduction in Q4 2024.","Cash and equivalents $1.3M at March 31, 2025, comparable to $1.4M at Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166556,"accession_number":"0001213900-25-039783","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences replaces auditor Marcum with CBIZ CPAs after acquisition of attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as independent auditor on May 2, 2025, due to CBIZ CPAs acquiring its attest business.","Audit Committee approved engagement of CBIZ CPAs as new independent registered public accounting firm same day.","Marcum's FY2024 audit report contained a going concern emphasis, but no adverse opinion or disclaimer.","No disagreements or reportable events occurred with Marcum during FY2024 or through resignation date.","Emmaus provided Marcum with a copy of this 8-K; Marcum's response letter (Exhibit 16.1) filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166555,"accession_number":"0001213900-25-031624","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences reports 2024 net revenue down 44% to $16.7M; net loss widens to $0.10/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $16.7M in 2024, down 44% from $29.6M in 2023 due to inventory shortage.","Loss from operations of $1.9M vs income of $3.5M in 2023.","Net loss $6.5M ($0.10 per share) vs net loss $3.7M ($0.07) in 2023.","Cash at Dec. 31, 2024: $1.4M, down from $2.5M a year earlier.","Management expects 2025 net revenues to reach or exceed 2024 levels."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":2406000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200570,"accession_number":"0001213900-24-100231","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q3 net revenue up 9% to $5.5M; net income $1.8M vs $0.07M YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $5.5M (+9% YoY) driven by Middle East sales; U.S. sales fell due to generic L-Glutamine competition.","Q3 income from operations $0.8M (vs $0.02M YoY); net income $1.8M ($0.03 EPS) vs $0.07M.","Nine-month net loss $4.7M ($0.07 per share) vs $4.9M loss in prior year; revenue down 41% due to inventory shortages.","Cash at Sept 30, 2024: $1.3M, down from $2.5M at Dec 31, 2023.","CEO expects full-year results materially lower than 2023; generic competition may affect future Endari sales."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":13361000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200569,"accession_number":"0001213900-24-094976","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Seah Lim resigns from Emmaus Life Sciences board for personal reasons","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Seah Lim resigned as director on November 4, 2024, citing personal reasons.","No replacement or successor director has been named at this time.","The company expressed gratitude for Dr. Lim's service and support."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200568,"accession_number":"0001213900-24-090765","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences engages Marcum LLP as new auditor for FY 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee appointed Marcum LLP as independent accountant on October 22, 2024.","Marcum will audit the quarter ended September 30, 2024 and year ending December 31, 2024.","Company did not consult Marcum on any matters described in Item 304(a)(2) of Reg S-K prior to engagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200567,"accession_number":"0001213900-24-085641","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences board changes: George Sekulich resigns, Jon Kuwahara appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Sekulich resigned from board on Sep 30, 2024, after his termination as Chief Commercial Officer on Oct 4.","Jon Kuwahara appointed to fill vacancy effective Oct 1, 2024; also named Chair of Audit Committee.","Kuwahara served as Emmaus director from Jan 2016 to Sep 2018; now VP-Finance at Crinetics Pharmaceuticals (CRNX).","No family relationships or transactions requiring disclosure under Item 404(a) exist.","Kuwahara is a CPA with a BBA from University of Hawaii; prior roles at Novus Therapeutics and other life sciences firms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216576,"accession_number":"0001213900-24-077411","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["2.02","4.01","9.01"],"status":"ready","headline":"Revenue falls 55% to $7.9M, net loss $6.5M; auditor Baker Tilly declines reappointment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue for H1 2024 was $7.9M, down 55% from $17.5M in H1 2023, due to inventory shortages.","Net loss of $6.5M ($0.10/sh) vs $5.0M ($0.10/sh) in prior year; operating loss $2.2M vs income $2.2M.","Cash at June 30, 2024: $1.5M, down from $2.5M at Dec 31, 2023.","CEO says full-year revenue unlikely to match 2023; generic L-Glutamine launch poses risk to Endari.","Auditor Baker Tilly notified Sept 5, 2024 it will not stand for reappointment; no disagreements but prior reports include going concern note."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216575,"accession_number":"0001213900-24-062226","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences appoints Willis Lee as CEO, eliminates interim Co-President role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Willis Lee appointed CEO effective July 15, 2024; previously interim Co-President and COO.","Lee continues as Chairman of the Board (since Oct 2023); compensation unchanged.","George Sekulich, former interim Co-President, continues as Chief Commercial and Information Officer.","Move eliminates the interim Co-President structure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216574,"accession_number":"0001213900-24-058821","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus 2023 revenue up 61% to $29.6M, net loss narrows to $3.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $29.6M (vs $18.4M in 2022); operating income $3.5M vs loss $6.6M.","Net loss $3.7M ($0.07/sh) vs $10.6M ($0.21/sh); cash $2.5M at Dec 31, 2023.","MENA region and U.S. sales drove growth; disposed of Japanese JV equity interest.","Inventory shortage impacted Q4 2023 sales; backlog ~$4.6M as of May 24, 2024; now resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":7883000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236240,"accession_number":"0001213900-24-047151","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Emmaus Life Sciences amends bylaws to establish exclusive forum for stockholder litigation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board adopted Amendment to Amended and Restated By-Laws on May 23, 2024.","Delaware Chancery Court designated as sole forum for derivative and internal affairs actions.","Federal district courts designated as exclusive forum for Securities Act claims.","Amendment effective immediately; shareholders deemed to have consented.","Exclusive forum provisions apply to actions based on duties, DGCL, and internal affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253925,"accession_number":"0001213900-24-016715","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences exchanges $9M maturing notes for new 10% notes due 2025; conversion price adjustable","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $9M principal of 2% convertible notes due Feb 24, 2024 for new 10% notes due Feb 24, 2025.","Conversion price initially $0.13/share, subject to quarterly decrease to equal VWAP; no additional consideration.","Principal and interest on new notes payable in two equal semi-annual installments.","Note holders joined Transfer Restriction and Voting Agreement, restricting resale and voting of conversion shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271386,"accession_number":"0001213900-23-097059","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["3.02","1.01","9.01"],"status":"ready","headline":"Emmaus exchanges $2.2M in director-held notes for 8.2M shares at $0.29/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged $1M note from Zen for 3,760,983 shares and $1.2M note from Lim for 4,447,426 shares.","Deemed per-share value of $0.29 represents a premium to Dec 14, 2023 OTCQX closing price.","Zen's note was convertible at $0.50/share, due on demand after Jan 24, 2024; Lim's note due Sep 16, 2025.","Total principal of $2.2M plus accrued interest canceled; no additional cash consideration paid.","Issuance exempt under Section 3(a)(9); directors Zen and Lim are the sole noteholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271385,"accession_number":"0001213900-23-086486","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.","Q3 income from operations $0.02M, compared to operating loss of $0.7M in Q3 2022.","Net loss for nine months 2023 was $4.9M ($0.09/share), improved from $10.8M ($0.22/share) in 2022.","Inventory shortage of Endari caused lower Q3 sales; remedied, expects recovery in Q4.","Cash and cash equivalents $1.5M at Sep 30, 2023, down from $2.0M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":22530000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271384,"accession_number":"0001013762-23-001586","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus appoints George Sekulich to board and Willis Lee as Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Sekulich appointed to fill board vacancy created by Yutaka Niihara's resignation on Sept 25, 2023.","Sekulich also serves as Co-President and Chief Commercial Officer; previously SVP and CIO since July 2019.","Willis Lee, Co-President and COO, appointed as Chairman of the Board of Directors on October 2, 2023.","No family relationships or related-party transactions with Sekulich were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288243,"accession_number":"0001213900-23-070110","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Emmaus CEO and Chairman steps down; interim Co-Presidents appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yutaka Niihara, M.D., Ph.D., leaves CEO and Chairman roles effective Aug 18, 2023, to pursue other projects; remains a director.","Willis Lee (COO) and George Sekulich (CIO) appointed interim Co-Presidents pending CEO search.","George Sekulich's base salary set at $210,000; eligible for stock plan awards.","Company to focus on Endari sales in U.S. and MENA, expects generic competition in 2024.","Discontinuing non-Endari activities to reduce operating costs and improve cash flow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288242,"accession_number":"0001213900-23-066904","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences reports record Q2 net revenue of $10.8M; posts $3.3M income from operations","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net revenue $10.8M (up 151% YoY); six-month net revenue $17.5M (up 133% YoY).","Q2 income from operations $3.3M vs loss of $1.4M in Q2 2022; six-month income $2.2M vs loss of $4.5M.","Net loss narrowed to $1.5M ($0.03/sh) from $8.9M ($0.18/sh) in Q2 2022; six-month loss $5.0M ($0.10) vs $10.4M ($0.21).","Sales growth driven by $4.1M increase in MENA region in Q2; U.S. sales also recovering.","Cash and equivalents $1.4M at June 30, 2023, down from $2.0M at Dec 31, 2022."],"consensus_eps_estimate":-0.0306,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":17512000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308707,"accession_number":"0001213900-23-039397","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences Q1 net loss $3.5M, revenue up 109% to $6.8M, cash dwindles","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $6.8M, up 109% YoY from $3.2M, driven by U.S. and MENA sales.","Loss from operations improved to $1.2M from $3.1M loss in Q1 2022.","Net loss $3.5M ($0.07 EPS) vs $1.5M ($0.03 EPS) a year ago, due to $3.7M other expense increase.","Cash $1.8M at March 31, 2023, down from $2.0M; working capital insufficient, needs additional financing.","Potential marketing approval for Endari in Saudi Arabia; fifth straight quarter of revenue growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":6753000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327476,"accession_number":"0001213900-23-025506","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences reports FY2022 net loss of $10.6M; going concern doubt raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues $18.4M, down 10.7% from $20.6M in 2021; operating loss widened to $6.6M from $6.1M.","Net loss attributable to common stockholders $10.6M ($0.21 per share) vs $15.9M ($0.32) in 2021.","Cash and cash equivalents $2.0M at Dec 31, 2022, down from $2.3M; substantial doubt about going concern.","Audit report includes going-concern qualification; company cites Covid disruptions and higher distributor discounts.","Marketing authorizations for Endari obtained in Qatar, Kuwait, and UAE in 2022; management cites strong sales momentum."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":6753000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327475,"accession_number":"0001213900-23-017895","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences issues convertible note to director for $1M and warrants for services","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Director loaned $1M via convertible note due demand after 1 yr, 10% interest, convertible at $0.50/share into 2M shares.","Two individuals received warrants for 250K shares each at $0.50/share for consulting services.","Consulting firm received 5-yr warrant for 500K shares at $0.47/share for services.","Total shares underlying instruments represent ~6% of pre-issuance common stock.","Securities issued without registration under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327474,"accession_number":"0001213900-23-003764","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2023-01-19T23:59:59+00:00","items":["3.02","5.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences grants CEO Yutaka Niihara warrant to purchase 7.5M shares at $4.50","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Niihara receives 5-year warrant for 7.5M shares at $4.50, fully vested on grant date.","Two consultants each receive 5-year warrants for 250K shares at $0.50.","Non-employee directors granted options for 100K shares each at $4.50, vesting quarterly over 1 year.","Executives (COO, CFO, others) granted options totaling 850K shares at $4.50 with multi-stage vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345185,"accession_number":"0001213900-22-078840","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Emmaus Life Sciences shareholders approve reverse stock split authorization and elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All five director nominees elected; Yutaka Niihara, MD received 23.2M votes for.","Approved amendment to authorize reverse stock split at ratio between 1:5 and 1:8 within one year.","Ratification of Baker Tilly as independent auditor for fiscal 2022 approved with 29.5M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345184,"accession_number":"0001213900-22-072481","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.","Q3 net loss $0.4M ($0.01/shr) vs $3.2M loss in Q3 2021; operating loss $0.7M vs $31k.","Cash and equivalents $1.2M vs $2.3M at Dec 31; working capital insufficient for next 12 months without restructuring.","First Endari sales in UAE (approved May 2022) and early access in GCC countries boosted Q3 revenue.","Company discussing restructuring or refinancing of indebtedness and other current liabilities."],"consensus_eps_estimate":0.0102,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":12460000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345183,"accession_number":"0001213900-22-062300","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-10-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Emmaus Life Sciences appoints Ian Zwicker and Dr. Seah Lim to Board; Lim loans $1.2M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ian Zwicker appointed to Board and as Chair of Audit Committee; will receive $25,000 for audit committee service.","Dr. Seah Lim appointed to fill Board vacancy; brings expertise in hematology, oncology, and sickle cell disease.","Dr. Lim loaned Emmaus $1.2M at 6% interest, due in 3 years, with one restricted share per $5 principal.","Loan proceeds used to augment working capital and for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361653,"accession_number":"0001213900-22-060657","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Masaharu Osato resigns from Emmaus Life Sciences board; two vacancies created","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Masaharu Osato resigned from the Board of Directors effective September 28, 2022, for personal reasons.","His departure leaves two vacancies on the five-person Board.","The Board is actively seeking candidates to fill the vacancies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361652,"accession_number":"0001213900-22-049677","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Emmaus Life Sciences obtains $1.9M in related-party loans at 10% to prepay debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["CEO Yutaka Niihara and wife loaned $1,576,574 net; includes $250k personal funds.","Two promissory notes ($1,668,751 and $250,000) due Aug 2027, 10% interest monthly.","Affiliate Hope International Hospice loaned $50,000 on demand note also at 10%.","Proceeds used to prepay $1,924,819 of third-party indebtedness.","Further related-party loans beyond previously reported in 2021/2022 filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361651,"accession_number":"0001213900-22-048141","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences reports Q2 2022 net loss of $8.9M; warns of insufficient working capital for 12 months","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenues Q2 2022 $4.3M, down 34% YoY from $6.5M; sequentially up 33% from Q1 2022 $3.2M.","Net loss Q2 2022 $8.9M ($0.18/sh) vs net income $2.5M ($0.05/sh) in Q2 2021.","Cash and equivalents $1.0M at June 30, 2022, down from $2.3M at Dec 31, 2021.","Management says working capital insufficient for next 12 months without restructuring or new financing.","In discussions to restructure indebtedness; awaiting Saudi marketing approval decision."],"consensus_eps_estimate":0.0102,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":7521000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361650,"accession_number":"0001213900-22-046326","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Director Robert Dickey IV resigns over disagreement with management on financial disclosures","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Dickey IV resigned from Emmaus board and audit committee effective Aug 4, 2022, citing disagreement with management.","Management provided data showing improved monthly sales since Q4 2021/Q1 2022 and projections for growth and debt paydown.","Dickey disagreed with the timeliness and adequacy of the information provided by management.","The resignation letter is filed as Exhibit 99.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381043,"accession_number":"0001213900-22-032224","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Three Emmaus directors resign after dispute with CEO over financial oversight and cost cuts","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lori Teranishi, Alfred Lui, and Jane Pine Wood resigned June 8, 2022, at CEO Yutaka Niihara's request.","Directors stated resignations followed their repeated requests for financial information and business plans.","CEO takes voluntary 30% salary reduction for three months; other senior management take 10% cuts.","Non-essential spending cut, including suspension of EJ Holdings facility retrofitting in Ube, Japan.","Company expects positive operating income later this year via increased Endari sales in U.S. and UAE/GCC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381042,"accession_number":"0001213900-22-026112","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Q1 revenue drops 40% to $3.2M; cash falls to $0.8M; working capital insufficient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $3.2M, down from $5.3M YoY; sell-through improved but overstocking by distributors hit revenue.","Net loss to common stockholders $1.5M ($0.03/share), improved from $8.4M loss ($0.17/share) in Q1 2021.","Loss from operations widened to $3.1M from $1.6M; operating expenses reduced to $5.3M from $6.5M.","Cash $0.8M at March 31, 2022; management says working capital insufficient for 2022 without additional financing.","Launched Endari telehealth program; Florida Medicaid added Endari to preferred drug list; received UAE marketing authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":3234000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399071,"accession_number":"0001213900-22-016970","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.","Operating loss $6.1M vs $32,000 loss in 2020; R&D and selling expenses increased.","Net loss attributable to common $15.9M ($0.32 per share) vs net income $1.4M ($0.03) in 2020.","Cash $2.3M at Dec 31, 2021; Endari added to Florida Medicaid preferred drug list, UAE approval obtained.","Licensed IRAK4 inhibitor from Kainos for cancer; telehealth partnership with UpScript launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":3234000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399070,"accession_number":"0001213900-22-001304","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Emmaus Life Sciences appoints Lori Teranishi as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 7 to 8 on Jan 6, 2022; Teranishi appointed.","Teranishi is founder & CEO of iQ 360, a strategic communications firm.","She will receive standard non-employee director compensation per proxy.","Expected to join board committees when schedule allows.","No family relationships or related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418060,"accession_number":"0001213900-21-062296","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2021-11-29T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Emmaus shareholders approve reverse split authorization and 2021 stock plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split authorization approved: 29,399,449 for, 540,130 against, 90,183 withheld.","2021 Stock Incentive Plan approved: 25,609,777 for, 433,820 against, 36,796 withheld.","Seven directors elected: Yutaka Niihara, Willis C. Lee, Robert Dickey IV, Masaharu Osato, Jane Pine Wood, Wei Peu Zen, Alfred Lui.","Advisory say-on-pay vote approved: 25,543,032 for, 497,065 against; board set frequency at every three years.","Baker Tilly US, LLP ratified as independent auditor for FY2021: 29,935,626 for, 44,800 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418059,"accession_number":"0001213900-21-052291","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2021-10-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Emmaus Life Sciences licenses IRAK4 inhibitor KM10544 from Kainos for cancer treatment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive license for U.S., U.K., EU to Kainos' IRAK4 inhibitor KM10544 for cancers including leukemia, lymphoma, solid tumors.","Six-figure upfront cash payment; mid-eight-figure milestones; single-digit royalty on net sales; similar sublicensing fee.","Emmaus plans in-vivo studies, IND-enabling studies, and seeks Orphan Drug Designation.","Agreement expands existing R&D collaboration between Emmaus and Kainos."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435624,"accession_number":"0001213900-21-041160","cik":822370,"company_name":"Emmaus Life Sciences, Inc.","ticker":"EMMA","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["4.02","9.01"],"status":"ready","headline":"Emmaus restates 2020 financials; net income rises to $1.4M from $1.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-reliance on FY2020 financials due to equity method investment misstatement; restated 10-K/A filed with unqualified audit opinion.","Net income restated to $1.4M from $1.1M; increase of $254K and $0.01 EPS from corrected equity in losses of Japanese affiliate EJ Holdings.","Original audit opinion had qualification; now eliminated with complete audit of affiliate financials.","Trading on OTC Pink could be suspended if Q1 and Q2 2021 10-Qs not filed by September 28, 2021; company striving to file promptly.","Interim Endari® sales volumes previously reported; full Q1 and Q2 2021 results expected in upcoming 10-Q filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":701883.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}